Thyrocare’s Bharat Aarogyam score flags silent health risks in 9 out of 10 Indians

Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s

Apollo report warns India’s silent health risks are striking earlier among young adults

Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Orca Bio’s Orca-T FDA review extended to July 2026

Middle East disruption hits thousands of global clinical trials, Phesi warns

The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment